Barrett’s esophagus (BE) is a premalignant condition with potential to progress to esophageal adenocarcinoma. In the general population, the incidence and prevalence are increasing based on recent data. Newer studies, including a recent meta analysis, report an association of metabolic syndrome (MS) with an increased risk of BE.
Single-center, retrospective cohort study of patients who had both MS and BE with biopsy-proven HGD vs. LGD during a 5-year period. Descriptive statistics were used to summarize clinical categorical variables into frequencies and percentages. The chi-squared test was performed to make the statistical comparisons of categorical and continuous variables, respectively.
308 patients with MS were included in the study, 125 had BE with HGD and 183 had BE with LGD. The proportion of metabolic syndrome in HGD patients was not significantly higher than LGD patients (27.2% vs. 25.7%, P = 0.77). Based on our results, HGD patients were 8.1% more likely to experience metabolic syndrome than LGD patients, although the result was not significant (OR 1.081; 95% CI 0.646 – 1.809).
While there is an association of metabolic syndrome resulting in an increased risk for BE based on recent studies, our results show that there is not a stronger association of MS in patients with HGD compared to LGD.